H.C. Wainwright analyst Matthew Caufield assumes coverage on Akebia Therapeutics (NASDAQ: AKBA) with a Buy rating and a price target ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE